ONC
BeOne Medicines
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- BeOne Medicines presented new Phase 3 survival data reinforcing the benefit of ZIIHERA-containing regimens in first-line HER2-positive gastroesophageal cancerAug 31, 2026
- BeOne Medicines received U.S. FDA approval for a TEVIMBRA-based regimen as first-line treatment for HER2-positive gastroesophageal adenocarcinomaAug 26, 2026
- BeOne Medicines, BeOne Care Foundation, and The Max Foundation renewed their partnership to expand access to BRUKINSA for chronic lymphocytic leukemia in low- and middle-income countriesAug 18, 2026
- BeOne Medicines expands U.S. manufacturing with more than $1 billion investment to support innovative cancer therapiesJul 23, 2026
- BeOne Medicines reported positive Phase 3 results for BRUKINSA in frontline mantle cell lymphomaJul 1, 2026